Masimo(MASI.US)控告美國海關準蘋果(AAPL.US)進口配備血氧讀取技術Apple Watch
醫療監測技術公司Masimo(MASI.US)控告美國海關及邊境保護局,因該局批準蘋果(AAPL.US)在兩間公司發生專利糾紛期間進口有血氧讀取技術的Apple Watch。
Masimo在訴訟中表示,該局錯誤地認定蘋果可以進口帶有脈搏血氧讀取技術的手錶,並在未通知 Masimo的情況下推翻去年的決定,因此要求華盛頓法院暫停該局的裁決,並繼續阻止蘋果銷售具有讀取血氧功能的手錶。
此前,Masimo指控蘋果挖走員工,並竊取其血氧技術用於Apple Watch,Masimo已在聯邦法院控告蘋果侵犯專利及竊取商業機密。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.